[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"squamous-cell-carcinoma-skin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:squamous-cell-carcinoma-skin":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":13,"conditions":25,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100601788","phase-1-a-study-to-investigate-safety-of-azd6750-in-adult-participants-with-select-advanced-or-metastatic-solid-tumors-100601788",false,"NCT07115043","A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","A Phase I\u002FII Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors","Inclusion criteria:\n\n* Participant ≥ 18 year\n* ECOG PS of 0 to 1\n* Provision of 'archival' tumor specimen\n* At least one measurable lesion according to RECIST v1.1,\n* Minimum life expectancy of 12 weeks\n* Adequate and stable cardiac function\n* Adequate bone marrow, liver and kidney function\n* Body weight ≥ 35 kg\n* Capable of giving signed informed consent\n\nModule 1 specific inclusion criteria:\n\n• Participants with locally advanced or metastatic select solid tumors (MM, Squamous cell carcinoma of skin, MCC, NSCLC, Head and neck squamous cell carcinoma, Gastric cancer\u002Fgastroesophaegeal junction cancer, RCC, HGSOC, Triple negative breast cancer) who have received adequate SoC\n\nModule 2 specific inclusion criteria:\n\n* Participants with Stage IV NSCLC Dose Escalation\u002FBackfills\n\n  1. Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapy if locally available OR\n  2. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.\n\n     Dose Expansion\n\n  \u003C!-- -->\n\n  1. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.\n\n     Exclusion criteria:\n* Any evidence of:\n\nSevere or uncontrolled systemic diseases including respiratory, cardiac or tumor-related conditions\n\n* History or planned organ or allogeneic stem cell transplantation.\n* Active or prior documented autoimmune or inflammatory disorders, within the past 3 years\n* Any prior toxicities that led to permanent discontinuation of prior immunotherapy\n* Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy\n* Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids\n* Acute untreated or symptomatic malignant spinal cord compression, or a history of leptomeningeal carcinomatosis.\n* Active uncontrolled or chronic infection of hepatitis B, hepatitis C\n* Prior history of Grade ≥ 3 non-infectious pneumonitis.\n* Participant requires chronic immunosuppressive therapy (including steroids \\> 10 mg prednisone\u002Fday or equivalent).\n* Receipt of live attenuated vaccine within 30 days.\n\nModule 2 specific exclusion criteria:\n\n* Previous treatment with anti-TIGIT therapy\n* 1L NSCLC participants with genetic alteration such as EGFR that has a targeted therapy in 1L as per local SoC","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2",[26,27,28,29,30,31,32,33,34],"Melanoma","Non-small Cell Lung Cancer","Squamous Cell Carcinoma (Skin)","Renal Cell Carcinoma","Merkel Cell Carcinoma","Triple Negative Breast Cancer","Head and Neck Squamous Cell Carcinoma","Gastric Cancer\u002FGastroesophageal Junction Cancer","High Grade Serous Ovarian Carcinoma","RECRUITING","2026-06-10",{"date":38,"type":39},"2026-06-11","ACTUAL",{"date":41,"type":39},"2025-07-29",{"date":43,"type":20},"2029-10-02",{"name":45,"class":46},"AstraZeneca","INDUSTRY",13,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100545603","skin-cancer-and-hyperthermia-and-radiotherapy-100545603","NCT06384053","Skin Cancer and Hyperthermia and Radiotherapy","Skin Cancer and Hyperthermia and Radiotherapy - SAHARA a Two-arm, Open-label, Randomized Controlled Phase II Trial","SAHARA","Inclusion Criteria:\n\n* Personally signed and dated written informed consent\n* Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of any differentiation\n* ≥ T2 (TNM Classification 8th Edition)\n* Tumor thickness up to 2cm (Maximum Depth invasion and\u002For exophytic growth, measured on pathology report or imaging)\n* Local recurrence allowed, if primary treatment longer ago than 6 months (after primary treatment other than radiotherapy (RT))\n* Age ≥ 65 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2, with a life expectancy of more than 6 months\n* Presentation at the Swiss Hyperthermia Network (SHN) tumor conference mandatory\n\nExclusion Criteria:\n\n* Other histology than BCC or SCC\n* T1 tumor and\u002For N+ (according to TNM classification 8th edition)\n* Tumors after resection (R1 or R2 as well as adjuvant indication)\n* Tumor invasion into critical areas\n* Several lesions exceeding the capacity of one treatment\u002Fradiation field (multiple lesions within one treatment field are acceptable)\n* Previous (one month) or concurrent Chemo- or Immunotherapy\n* Patients with connective tissue disorders (e.g. Sclerodermia, Lupus erythematodes)\n* Lesions inside or in proximity (within 3cm) previously irradiated area\n* Medical immunosuppression\n* wIRA-specific exclusion criteria\n\n  * Tattoos in irradiated area\n  * Increased photosensitivity (either due to simultaneous treatment with photosensitivity-enhancing medications or conditions such as porphyria)","65 Years",{"count":58,"type":20},100,[60],"NA","The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).",[63,64,65],"Basal Cell Carcinoma","Squamous Cell Carcinoma Skin","Non-melanoma Skin Cancer",[67,68,69,70,71,72,73],"BCC","SCC skin","w-IRA hyperthermia","radiotherapy for non-melanoma skin cancer","non-melanoma Skin cancer","w-IRA combined with RT","hyperthermia","2025-06-11",{"date":76,"type":39},"2025-06-15",{"date":78,"type":39},"2025-01-01",{"date":80,"type":20},"2028-07-01",{"name":82,"class":83},"Kantonsspital Winterthur KSW","OTHER",4,"Squamous Cell Carcinoma, Skin"]